Barbara L, Biasco G, Capurso L, Dobrilla G, Lalli A, Paganelli G M, Pallone F, Torsoli A
Istituto di Clinica Medica e Gastroenterologia, Università di Bologna, Italy.
Am J Gastroenterol. 1990 Sep;85(9):1109-13.
We conducted a double-blind randomized treatment study on patients affects by non-ulcer dyspepsia in whom multiple biopsy specimens showed active gastritis. Patients were given either 3 g/day of sucralfate (n = 39) or 600 mg/day of sulglycotide (n = 50) for 6 wk, a glycopeptide isolated from pig duodenum constituents. Endoscopy was carried out at baseline and at the end of treatment. We took biopsies from the gastric body (twice) and antrum (six times) at each endoscopy in order to determine grade and extent of gastritis and Helicobacter pylori colonization. Both treatments induced a marked regression of active gastritis (sucralfate group: p less than 0.05 and p less than 0.0001, respectively, in body and in antrum; sulglycotide group: p less than 0.01 and p less than 0.001, respectively). Conversely, Helicobacter pylori colonization remained unchanged at the end of the treatments. At baseline, a close relationship was found between grade of active inflammation in each biopsy and Helicobacter pylori density. After therapy, the association was lost in each treatment group. These results suggest that there can be a remission of active gastritis in patients with non-ulcer dyspepsia even without changes in Helicobacter pylori colonization. This result can be achieved by enhancing the protective properties of the gastric mucosa.
我们对受非溃疡性消化不良影响且多个活检标本显示有活动性胃炎的患者进行了一项双盲随机治疗研究。患者被给予每日3克的硫糖铝（n = 39）或每日600毫克的舒糖肽（n = 50），为期6周，舒糖肽是从猪十二指肠成分中分离出的一种糖肽。在基线和治疗结束时进行内镜检查。每次内镜检查时，我们从胃体（两次）和胃窦（六次）取活检，以确定胃炎的分级和范围以及幽门螺杆菌定植情况。两种治疗均使活动性胃炎明显消退（硫糖铝组：胃体和胃窦分别为p < 0.05和p < 0.0001；舒糖肽组：分别为p < 0.01和p < 0.001）。相反，治疗结束时幽门螺杆菌定植情况保持不变。在基线时，发现每次活检中活动性炎症的分级与幽门螺杆菌密度之间存在密切关系。治疗后，每个治疗组中这种关联消失。这些结果表明，即使幽门螺杆菌定植情况没有改变，非溃疡性消化不良患者的活动性胃炎也可能缓解。通过增强胃黏膜的保护特性可以实现这一结果。
